T1	Intervention 23 57	repeated use of ulipristal acetate
T2	Intervention 61 77	uterine fibroids
T3	Intervention 180 198	ulipristal acetate
T4	Intervention 203 257	intermittent treatment of symptomatic uterine fibroids
T5	Intervention 332 350	ulipristal acetate
T6	Intervention 266 305	Double-blind, randomized administration
T7	Intervention 420 447	symptomatic uterine fibroid
T8	Intervention 455 469	heavy bleeding
T9	Intervention 487 525	Two repeated 12-week treatment courses
T10	Intervention 549 567	ulipristal acetate
T11	Intervention 593 603	Amenorrhea
T12	Intervention 665 669	pain
T13	Intervention 642 657	quality of life
T14	Intervention 626 640	fibroid volume
T15	Intervention 605 624	controlled bleeding
T16	Intervention 701 717	treatment groups
T17	Intervention 767 777	amenorrhea
T18	Intervention 790 807	treatment courses
T19	Intervention 843 862	controlled bleeding
T20	Intervention 870 891	two treatment courses
T21	Intervention 903 915	Menstruation
T22	Intervention 935 951	treatment course
T23	Intervention 985 993	baseline
T24	Intervention 1030 1079	median reductions from baseline in fibroid volume
T25	Intervention 1005 1028	second treatment course
T26	Intervention 1139 1157	ulipristal acetate
T27	Intervention 1173 1185	Pain and QoL
T28	Intervention 1198 1209	both groups
T29	Intervention 1211 1229	Ulipristal acetate
T30	Intervention 1279 1324	discontinuing treatment due to adverse events
T31	Intervention 1340 1364	Repeated 12-week courses
T32	Intervention 1368 1397	daily oral ulipristal acetate
T33	Intervention 1424 1489	control bleeding and pain, reduce fibroid volume, and restore QoL
T34	Intervention 1507 1527	symptomatic fibroids
T35	Intervention 1529 1543	CLINICAL TRIAL
